The effect of cilnidipine on sympathetic nerve activity and glycemic control in type 2 diabetic patients

The effect of cilnidipine on sympathetic nerve activity and glycemic control in type 2 diabetic patients - The effect of cilnidipine on sympathetic nerve activity and glycemic control in type 2 diabetic patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004926

Enrollment

Registered

2011-02-01

Start date

2011-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus Hypertension

Interventions

cilnidipine calcium channel blockers other than cilnidipine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients who showed writtten informed consent to take part in this trial. 2. Type 2 diabetic patients 3.Patients whose blood pressure is 130/80 mmHg ot higher 4. Patients taking calcium channel bloker other than cilnidipine for 3 months or longer

Exclusion criteria

Exclusion criteria: 1. Malignant hypertension 2. (possible) pregnant women 3. Severe liver dysfunction 4. History of severe side effects to calcium channel blockers 5. Patients who was considered to be difficult to take part in this trial by physician in charge

Design outcomes

Primary

Measure	Time frame
serum catecholamine concentration value of HbA1c	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026